CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
everolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00770120
NCT00770120Phase 2Completed
CompareCT.gov

Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)

SWOG Cancer Research Network·interventional·Posted Oct 9, 2008·Updated Mar 6, 2020

In Brief

A Phase 2 clinical trial evaluating everolimus for Malignant Mesothelioma. Completed, enrolled 61 participants across 129 sites.

Detailed Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant mesothelioma that cannot be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 9, 2008
Enrollment StartDec 1, 2008
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.7 years ago

Interventions

everolimusdrug